

Company Overview

Axogen (AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. Axogen's portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Along with these core surgical products, Axogen also offers AxoTouch® Two-Point Discriminator and AcroVal® Neurosensory & Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom and several European and international countries.

Axogen to Participate in the 74th Annual American Society for Surgery of the Hand Meeting

Aug 27 2019, 7:00 AM EDT

Axogen, Inc. Reports 2019 Second Quarter Financial Results

Aug 6 2019, 4:01 PM EDT

Axogen, Inc. to Participate at Canaccord Genuity 39th Annual Growth Conference

Jul 29 2019, 7:00 AM EDT

Stock Overview

Symbol	AXGN
Exchange	Nasdaq
Shares OS	38,672,871
Market Cap	\$554.96M
Last Price	\$14.35
52-Week Range	\$11.82 - \$39.33

09/13/2019 04:00 PM EDT

Investor Relations

Axogen, Inc.
13631 Progress Blvd.
Suite 400
Alachua, FL 32615
InvestorRelations@AxogenInc.com

Board of Directors

Karen Zaderej
Chairman, Chief Executive Officer, and President

Mark Gold M.D.
Director

Amy Wendell
Lead Director

Guido J. Neels
Director

Robert J. Rudelius
Director

Gregory G. Freitag
General Counsel

Quentin S. Blackford
Director

Alan M. Levine
Director

Axogen, Inc.

13631 Progress Blvd
Suite 400
Alachua, FL 32615

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.